Highly selective and potent inhibitor of cyclooxygenase-2 (IC50=10nM for COX-2 versus IC50=17.8µM for COX-1) with antitumor properties. Exhibits longer half-life time and reduced gastric toxicity in fasting rat model. Has antitumor properties and has been shown to induce apoptosis and bFGF and VEGF-driven angiogenesis. Potent antimetastatic activity against both spontaneous metastases arising following primary tumour excision and experimental metastases.
Product Details
| Alternative Name: | 4-[5-(4-Chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide |
| |
| Formula: | C16H11ClF3N3O2S |
| |
| MW: | 401.8 |
| |
| CAS: | 170569-86-5 |
| |
| Purity: | ≥95% (HPLC) |
| |
| Appearance: | White to off-white crystalline powder. |
| |
| Solubility: | Soluble in DMSO. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 2 years after receipt when stored at -20°C. Stock solutions are stable for 3 months when stored at -20°C. |
| |
| Handling: | Protect from light. Packaged under inert gas. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Cyclooxygenase-2 inhibitor (SC-236) suppresses activator protein-1 through c-Jun NH2-terminal kinase: B.C. Wong, et al.; Gastroenterology
126, 136 (2004),
Abstract;
Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway: X.H. Jiang, et al.; Oncogene
21, 6113 (2002),
Abstract;
Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia: P.A. Lapchak, et al.; Stroke
32, 1220 (2001),
Abstract;
Full Text
Prostaglandins are required for CREB activation and cellular proliferation during liver regeneration: D.A. Rudnick, et al.; PNAS
98, 8885 (2001),
Abstract;
Full Text
Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats: X. Guo, et al.; Eur. J. Pharmacol.
411, 193 (2001),
Abstract;
Cyclooxygenase-2 inhibitor SC-236 attenuates mechanical allodynia following nerve root injury in rats: T.A. Deleo, et al.; J. Orthop. Res.
18, 977 (2000),
Abstract;
Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia: C. Bandeira-Melo, et al.; J. Immunol.
164, 1029 (2000),
Abstract;
Full Text
Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor: C. Petersen, et al.; Clin. Cancer Res.
6, 2513 (2000),
Abstract;
Full Text
Inhibition of cyclooxygenase-2 decreases DNA synthesis induced by platelet-derived growth factor in Swiss 3T3 fibroblasts: E. Castano, et al.; J. Pharmacol. Exp. Ther.
293, 509 (2000),
Abstract;
Full Text
COX-2 inhibitors. A new class of antiangiogenic agents: J.L. Masferrer, et al.; Ann. NY Acad. Sci.
889, 84 (1999),
Abstract;
Prostaglandin E(2) mediates inhibition of insulin secretion by interleukin-1beta: P.O. Tran, et al.; J. Biol. Chem.
274, 31245 (1999),
Abstract;
Full Text
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib): T.D. Penning, et al.; J. Med. Chem.
40, 1347 (1997),
Abstract;
A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors: J.K. Gierse, et al.; J. Biol. Chem.
271, 15810 (1996),
Abstract;
Full Text
